Novel Antiplatelet Therapies for Atherothrombotic Diseases. Issue 4 (April 2019)

• Record Type: Journal Article
• Authors: Majithia, Arjun; Bhatt, Deepak L.
• Is Part Of: Arteriosclerosis, thrombosis, and vascular biology. Volume 39:Issue 4(2019)
• Publication Date: 2019-04
• Subjects: acute coronary syndrome -- cardiovascular disease -- hemostasis -- myocardial infarction -- thrombosis; Arteriosclerosis -- Periodicals; Thrombosis -- Periodicals; Blood-vessels -- Pathophysiology -- Periodicals; Electronic journals; 616.13
• DOI: 10.1161/ATVBAHA.118.310955
• Languages: English
• ISSNs: 1079-5642

Abstract

Abstract : Antiplatelet therapies are an essential tool to reduce the risk of developing clinically apparent atherothrombotic disease and are a mainstay in the therapy of patients who have established cardiovascular, cerebrovascular, and peripheral artery disease. Strategies to intensify antiplatelet regimens are limited by concomitant increases in clinically significant bleeding. The development of novel antiplatelet therapies targeting additional receptor and signaling pathways, with a focus on maintaining antiplatelet efficacy while preserving hemostasis, holds tremendous potential to improve outcomes among patients with atherothrombotic diseases.